Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2621]

UT Southwestern develops test to predict immunotherapy response in kidney cancer

UT Southwestern develops test to predict immunotherapy response in kidney cancer

Immunotherapy drug found safe in treating cancer patients with HIV

Immunotherapy drug found safe in treating cancer patients with HIV

ASCO 2019: NCI-MATCH trial finds the combination of dabrafenib and trametinib effective

ASCO 2019: NCI-MATCH trial finds the combination of dabrafenib and trametinib effective

ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer

ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer

ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer

ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung...

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung...

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

More from ecancer